Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: A randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) study

European Heart Journal

Volumn 24, Issue 13, 2003, Pages 1216-1222

  Strandberg, Timo E ^a   Pitkala, Kaisu ^a   Berglind, Saila ^a   Nieminen, Markku S ^a   Tilvis, Reijo S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Cardiovascular prevention; Drugs; Elderly; Multifactorial

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; WARFARIN;

AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVIDENCE BASED MEDICINE; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; LIFESTYLE; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HUMANS; MALE; QUALITY OF LIFE; RISK FACTORS;

EID: 0037772214     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(03)00240-9     Document Type: Article

References (24)

1. Williams MA, Fleg JL, Ades PA et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients >=75 years of age. An American Heart Association Scientific Statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation 2002;105:1735-43.
2. Lee PY, Alexander KP, Hammill BG et al. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA 2001;286(6):708-13.
3. Strandberg TE, Pitkälä K, Bergling S et al. Multifactorial cardiovascular disease prevention in patients aged 75 years and older: a randomized controlled trial. Am Heart J 2001;142:945-51.
4. Boult C, Boutt LB, Morishita L et al. A randomized clinical trial of outpatient geriatric evaluation and management. J Am Geriatr Soc 2001;49:351-9.
5. McAlister FA, Lawson FME, Teo KK et al. Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. Br Med J 2001;323:957-62.
6. Hebert R, Robichaud L, Roy P-M et al. Efficacy of a nurse-led multidimensional preventive programme for older people at risk of functional decline. A randomized controlled trial. Age Ageing 2001;30:147-53.
7. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998;19:1434-503.
8. Sintonen H. The 15D instrument of heatlh-related quality of life: properties and applications. Ann Med 2001;33:328-36.
9. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.
10. Nolan PE Jr, Marcus FI. Cardiovascular drug use in the elderly. Am J Geriatr Cardiol 2000;9:127-9.
11. Halkin A, Keren G. Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 2002;112:126-34.
12. Ahmed A, Kiefe CI, Allman RM et al. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc 2002;50:1659-66.
13. Tuomilehto J, Lindstrom J, Eriksson JG et al. For the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
14. Knowler WC, Barrett-Connor E, Fowler SE et al. For the Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403.
15. Kesteloot H, Sans S, Kromhout D. Evolution of all-causes and cardiovascular mortality in the age group 75-84 years in Europe during the period 1970-1996; a comparison with worldwide changes. Eur Heart J 2002;23:384-98.
16. Beck AM, Ovesen L, Schroll M. A six months' prospective follow-up of 65+-year-old patients from general practice classified according to nutritional risk by the Mini Nutritional Assessment. Eur J Clin Nutr 2001;55:1028-33.
17. Whelton PK, Appel LJ, Espeland MA et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized trial of non-pharmacologic interventions in the elderly (TONE). JAMA 1998;279:839-46.
18. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001;20(9290):1305-15.
19. Grimm RH Jr, Margolis KL, Papademetriou W et al. Baseline Characteristics of Participants in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2001;37:19-27.
20. Hypertension in the Very Elderly Trial (HYVET). Protocol for the main trial. Drugs Aging 2001;18(3):151-64.
21. Ridker PM. Should statin therapy be considered for patients with elevated C-reactive protein? The need for a definitive clinical trial. Eur Heart J 2001;22:2135-7.
22. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22.
23. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER); a randomised controlled trial. Lancet 2002;360:1623-30.
24. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol >=125 mg/dl treated with statins versus no lipid-lowering drugs. Am J Cardiol 2002;89:67-9.